Special Issue "Novel Bioactive Macrolides: Design, Preparation, Properties"
Deadline for manuscript submissions: closed (31 October 2021).
Interests: macrolide antibiotics; drug design; biomolecular interactions; structural analysis; hydrogen bonds; hyphenated analytical systems
Interests: macrolide antibiotics; biomolecules; organic synthesis; ligand–receptor interactions; analysis of complex mixtures; reaction monitoring; polymorph identification
Macrolide antibiotics belong to a class of macrolide molecules consisting of a central 12–16-membered macrolactone ring and one or more sugar units attached to it. The main representatives include erythromycin, azithromycin, clarithromycin and telithromycin. They have widely been prescribed for the treatment of upper and lower respiratory tract infections owing to their high efficacy and safety. Macrolides bind to the ribosomal 23S rRNA at or near the peptidyl transferase center and block the exit of the nascent peptide. Although the crystal structures of some ribosome–macrolide complexes have been solved recently, which threw new light on the binding mechanisms of macrolides to ribosomes and served as a platform for drug design, there are still no new macrolide antibiotics on the market.
On the other hand, emerging multi-drug-resistant microbial pathogens demand the discovery of novel and more effective antimicrobial agents. Despite the modern tools and approaches that have been developed lately in medicine, biology and chemistry, rising microbial resistance still poses serious challenges and risks to human health. The World Health Organization has recognized the treat and considers it to be the most urgent issue to deal with. Therefore, there is a great demand for the discovery of novel, more potent and safer macrolides that are active against resistant pathogenic bacteria.
This Special Issue will cover recent developments in the field of the discovery and applications of new bioactive macrolides. It is aimed at giving insights into the design and strategies used to synthesize new materials with improved bioactivities and overall biological profile. Structural characterization, evaluation of physico-chemical properties, interactions with biological receptors and establishing structure-property relationships will also be considered in this issue.
Prof. Dr. Predrag Novak
Prof. Dr. Tomislav Jednačak
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug design